Urinary biomarkers of tubular injury in chronic kidney disease. by Caplin, Ben & Nitsch, Dorothea
Caplin, B; Nitsch, D (2016) Urinary biomarkers of tubular injury
in chronic kidney disease. Kidney international, 91 (1). pp. 21-23.
ISSN 0085-2538 DOI: https://doi.org/10.1016/j.kint.2016.10.003
Downloaded from: http://researchonline.lshtm.ac.uk/3298902/
DOI: 10.1016/j.kint.2016.10.003
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Urinary Biomarkers of Tubular Injury in Chronic Kidney Disease 
Ben Caplin1* and Dorothea Nitsch2 
 
1. Centre for Nephrology, UCL Medical School.  
2. Department of Non-communicable Disease Epidemiology. London School of 
Hygiene and Tropical Medicine. 
 
*Correspondence: Ben Caplin, Centre for Nephrology, UCL Medical School, Rowland 
Hill Street, London NW3 2PF. b.caplin@ucl.ac.uk 
 
Keywords: CKD progression; Kidney injury molecule-1; Neutrophil gelatinase-
associated lipocalin; N-acetyl-β-D-glucosamininidase; Liver fatty acid-binding protein;  
 
Abstract: It has been suggested that urinary biomarkers of tubular injury might 
help predict progression to end-stage renal disease. In this issue Hsu et al. report, 
that in those with established CKD, this information doesn’t add to what we know 
by quantifying creatinine and albuminuria. Here we discuss the evidence for 
urinary tubular injury markers in predicting renal outcomes in CKD and the areas 
where measurement of these molecules might be useful in the future.  
 
Since chronic dialysis became widely available there has been substantial effort 
focused on understanding which of our patients will go on to require dialysis and/or 
kidney transplantation. Our duty as clinicians is to provide care founded on shared 
and informed decision making. This requires patients with chronic kidney disease 
(CKD) and their doctors to be able to access precise information about the risks of 
progression so as to plan for the future. This process also translates into hard clinical 
outcomes; for example, those who receive an adequate period of pre-dialysis 
preparation are more likely to start dialysis with definitive access and consequently 
are at lower risk of early complications and death. To this end biomarkers such as 
creatinine and albuminuria are established tools in helping determine who will go on 
to need dialysis but as a renal community, we should always be asking: Can we do 
this better?  
The search for predictive biomarkers has also been a focus of the Acute Kidney Injury 
(AKI) field where the failure of the serum creatinine to rise within a clinical useful 
window for intervention has made this a priority. Investigators have searched for 
and established the utility of markers of direct renal tubular damage. Kidney injury 
molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-
glucosamininidase (NAG) and liver fatty acid-binding protein (L-FABP) are all proteins 
that are released into the urine following acute injury to the renal tubule (Figure 1). 
A comprehensive review of the biology of these molecules is beyond this 
commentary but is available elsewhere.1 Given the increasing recognition of the 
interplay between CKD and AKI2 and the fundamental role of the tubular-interstitial 
compartment in progressive CKD it is intuitive that these urinary biomarkers might 
also provide important predictive information in chronic disease.  
A number of moderately sized studies, in cohorts without CKD at baseline but at high 
risk of developing renal impairment, have demonstrated useful additional power 
using tubular biomarkers (specifically NGAL) to predict outcomes such as incident 
stage 3 CKD.3 However, this doesn’t answer the question as to whether these novel 
urinary markers have predictive value in patients with established CKD. To date, 
studies have reported conflicting results on the utility of NGAL when added to 
traditional predictors of progressive renal disease such as baseline eGFR and 
albuminuria.4,5 Against this background the report by Hsu and colleagues in this issue 
of Kidney International provides additional clarification6. The authors report data 
from the Chronic Renal Insufficiency Cohort (CRIC) study on the associations 
between KIM1, NGAL, NAG and L-FABP and the combined outcome of end-stage 
renal disease (ESRD) or halving of eGFR, a conservative but specific and FDA 
approved end-point. Although all of the urinary biomarkers were associated with the 
outcome, none of them provide additional discrimination over and above baseline 
eGFR and urinary albumin excretion.  
These findings seem robust:  This is the largest cohort in which such an analysis has 
been performed. The patients included were recruited from multiple centres and 
with a broad range of underlying kidney diseases. Importantly methodological 
considerations surrounding possible biomarker degradation were controlled for. 
Finally the authors demonstrate that the outcomes of their analyses were not 
dependent on adjustment, or not, of biomarker levels for urinary creatinine 
concentration. This has been a controversial issue as although it is intuitive to use 
creatinine to control for differences urinary concentration, urinary creatinine levels 
will depend not only on overall urinary concentration but also creatinine production, 
something that may systematically differ between study participants with stable CKD 
and those with progressive disease.  
So what are the implications of these findings? Firstly, it is important to acknowledge 
that publication of what are fundamentally negative findings in high profile journal 
plays a crucial role in pursuit of scientific advancement. One has to wonder how 
many moderately sized but negative studies examining these associations never 
even made it to a first draft as the lead investigator considers the findings not 
worthy of the effort (and expense) needed to submit a manuscript. Following 
publication of this paper we can now say with some degree of certainty that tubular 
injury markers (at least KIM1, NGAL, NAG and L-FABP) aren’t likely to be helpful in 
predicting renal outcomes in a typical clinic population with CKD.  
Of course we should also ask what help from biomarkers are we are looking for? As 
the authors allude to when faced with a patient with established CKD in clinic we are 
already have pretty good tools to identify those who will progress to the need for 
dialysis. We routinely quantify eGFR and albuminuria which, unlike risk factors for 
atherosclerotic cardiac events such as hyperlipidaemia that predict occurrence of 
new disease, are markers of established pathology and/or physiological 
compensation and therefore provide a window onto the disease itself. Furthermore, 
if we add change in eGFR over time to our decision-making (something which the 
authors of this report did not do) we can increase our ability to determine who will 
progress to dialysis even further.7 Of course there remains a degree of uncertainty, 
and given the interplay between AKI and CKD one wonders whether this is explained 
by episodes of the former. The implication being that much of this uncertainty as to 
renal prognosis might not be possible to capture using biomarkers. After all, future 
information on the events that lead to AKI, e.g. the prescription of a nephrotoxic 
medication or the timing of the acquiring a bacterial pneumonia are unlikely to be 
obtainable from urine. 
So is this the end for urinary biomarker based research in CKD? We would argue no, 
but it means thinking more carefully about what we are trying to predict, why and in 
whom. Although the (change in) eGFR and albuminuria perform well in relatively 
advanced disease (i.e. eGFR<60mL/min) across all forms of CKD, perhaps research 
should focus on CKD where these pathological processes are not already established 
or alternatively on aetiologically distinct kidney condition(s) where a single disease 
process is at work.  
Early CKD, where the eGFR sits above the threshold of 60mL/min/m2, prior to the 
development of established glomerulosclerosis, might be a clinical scenario where 
urinary biomarkers might play a useful role. Indeed when Hsu and colleagues 
performed a post-hoc subgroup analysis in those at intermediate risk of progression 
(still a rather heterogeneous group) the inclusion of KIM-1 did marginally improve 
the prediction of renal outcomes.  
Furthermore there are subsets of patients with CKD who remain relatively free from 
albuminuria despite progression; tubular biomarkers may be useful in this 
population, and subgroup analyses of some cohorts support this approach.8 For 
example, young patients with Autosomal Dominant Polycystic Kidney disease may 
want to know their long-term prognosis to plan their professional and private life, 
yet it is incredibly difficult to predict at age 20 at what age an individual with this 
disease will reach ESRD. Similar issues pertain for patients with chronic allograft 
injury though the time frames are shorter. Thinking globally, a disease of interest 
might be CKD of undetermined cause (CKDu) where young agricultural workers from 
low and middle-income countries develop ESRD in the absence of known risk factors 
or albuminuria.9 Could identifying those with pre-clinical CKDu allow us to get a 
better insight in to the causes of this epidemic?  
Finally, biomarkers of progression are likely to become more important in the age of 
personalized medicine. If we are going to develop therapies to retard renal scarring 
we need to be able to stratify our patients who fall under the umbrella term CKD, 
not only by underlying aetiology but also by the activity of mediators of disease 
progression. Targeting specific (pro-inflammatory or pro-fibrotic pathways) is more 
attractive if the individuals who would benefit form these interventions can be 
identified and the effects of the intervention monitored over time. Given the 
shortage of effective treatments for progressive CKD it is perhaps with this last aim 
in mind that researchers should prioritize efforts in the search for novel biomarkers. 
Overall then, Hsu and colleagues work confirms what many suspect, not that we 
can’t identify novel markers of progressive kidney dysfunction in those with 
established CKD stage 3-5, but the tools we have to quantify risk of progression are 
already pretty accurate.  The future of urinary biomarkers in CKD is likely to be 
focused on either individual diseases, personalizing therapy targeted at renal scaring 
or in identifying those with preserved kidney function who might go on to develop 
some form of kidney impairment going forward.  
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Figure 1: Urinary biomarkers of tubular injury.  
Origin of the different markers measured in the report by Hsu et al. Kidney injury 
molecule-1 (blue) expression is upregulated on the surface of proximal tubular cells 
in response to injury; neutrophil gelatinase-associated lipocalin (yellow) is 
predominantly produced by inflammatory cells and released into blood and urine; N-
acetyl-β-D-glucosamininidase (green) is a constitutively expressed proximal tubular 
enzyme released following cell damage; liver fatty acid-binding protein (red) is a 
mitochondrial carrier protein which binds reactive oxygen species (black stars) and is 
released into the urine in response to cellular stress. Adapted from reference 1. 
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